

# Santos Castañeda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6103635/publications.pdf>

Version: 2024-02-01

196  
papers

5,055  
citations

94269

37  
h-index

114278

63  
g-index

206  
all docs

206  
docs citations

206  
times ranked

5478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteoarthritis associated with estrogen deficiency. <i>Arthritis Research and Therapy</i> , 2009, 11, 241.	1.6	236
2	Subchondral bone as a key target for osteoarthritis treatment. <i>Biochemical Pharmacology</i> , 2012, 83, 315-323.	2.0	220
3	Polymyalgia rheumatica. <i>Lancet, The</i> , 2017, 390, 1700-1712.	6.3	196
4	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. <i>Arthritis Research and Therapy</i> , 2010, 12, R152.	1.6	180
5	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
6	Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 71-80.	1.6	130
7	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	1.6	123
8	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	1.0	118
9	Efficacy of Tocilizumab in Conventional Treatment-Resistant Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 1659-1665.	2.9	115
10	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 717-723.	1.6	114
11	Estrogens, osteoarthritis and inflammation. <i>Joint Bone Spine</i> , 2013, 80, 368-373.	0.8	111
12	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. <i>Autoimmunity Reviews</i> , 2016, 15, 1013-1030.	2.5	107
13	Characterization of a new experimental model of osteoporosis in rabbits. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 53-59.	1.3	99
14	Cardiovascular disease in inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 851-869.	1.4	95
15	Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 618-626.	1.6	94
16	Efficacy of Anakinra in Refractory Adult-Onset Still's Disease. <i>Medicine (United States)</i> , 2015, 94, e1554.	0.4	93
17	Adult-onset Still's disease: Advances in the treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 222-238.	1.4	91
18	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78

#	ARTICLE	IF	CITATIONS
19	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. <i>Arthritis and Rheumatology</i> , 2019, 71, 2081-2089.	2.9	74
20	NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2012, 224, 426-429.	0.4	72
21	Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. <i>Autoimmunity Reviews</i> , 2018, 17, 301-315.	2.5	72
22	Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons. <i>Frontiers in Medicine</i> , 2020, 7, 601618.	1.2	67
23	Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 1-8.	1.6	66
24	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	1.6	66
25	Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. <i>Rheumatology</i> , 2020, 59, 3906-3916.	0.9	64
26	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	1.6	63
27	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	2.9	60
28	Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis. <i>PLoS ONE</i> , 2011, 6, e29492.	1.1	58
29	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	1.6	52
30	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1523-1525.	0.5	47
31	Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2021, 20, 102830.	2.5	47
32	Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 445-458.	1.5	46
33	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	2.5	46
34	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	1.6	44
35	IgA Vasculitis: Genetics and Clinical and Therapeutic Management. <i>Current Rheumatology Reports</i> , 2018, 20, 24.	2.1	44
36	Giant Cell Arteritis: Visual Loss Is Our Major Concern. <i>Journal of Rheumatology</i> , 2016, 43, 1458-1461.	1.0	41

#	ARTICLE	IF	CITATIONS
37	Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis. <i>Reumatología Clínica</i> , 2019, 15, 188-210.	0.2	40
38	Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. <i>Rheumatology International</i> , 2017, 37, 799-806.	1.5	37
39	Tocilizumab for the treatment of adult-onset Still's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 273-286.	1.4	37
40	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019, 46, 279-284.	1.0	36
41	Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2816.	1.0	36
42	A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. <i>Arthritis Research and Therapy</i> , 2010, 12, R50.	1.6	35
43	Brief Report: Association of HLA-DRB1*01 With IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2015, 67, 823-827.	2.9	35
44	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. <i>Arthritis Research and Therapy</i> , 2015, 17, 102.	1.6	33
45	An OA phenotype may obtain major benefit from bone-acting agents. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 421-428.	1.6	31
46	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1333-1338.	1.6	31
47	Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 608-615.	1.6	31
48	Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARDiovascular in rheuMATology study project. <i>Journal of Clinical Lipidology</i> , 2017, 11, 749-756.e3.	0.6	30
49	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.4	30
50	Early large vessel systemic vasculitis in adults. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101424.	1.4	29
51	Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2020, 72, 822-828.	1.5	28
52	Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients. <i>European Journal of Immunology</i> , 2021, 51, 634-647.	1.6	27
53	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. <i>Journal of Orthopaedic Research</i> , 2010, 28, 812-818.	1.2	26
54	Identification of a Untranslated Genetic Variant of <i>RARB</i> Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 351-360.	2.9	26

#	ARTICLE	IF	CITATIONS
55	Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. <i>Arthritis Research and Therapy</i> , 2015, 17, 211.	1.6	25
56	Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients. <i>PLoS ONE</i> , 2018, 13, e0202583.	1.1	25
57	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 69-75.	0.4	25
58	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. <i>Rheumatology International</i> , 2017, 37, 1239-1248.	1.5	24
59	Anakinra for the treatment of adult-onset Still's disease. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 979-992.	1.3	23
60	Inflammatory Arthritis and Heart Disease. <i>Current Pharmaceutical Design</i> , 2018, 24, 262-280.	0.9	22
61	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 717-723.	1.4	20
62	Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R146.	1.6	19
63	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 465-473.	0.4	19
64	A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.5	18
65	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	1.3	17
66	Deregulated PSGL-1 Expression in B Cells and Dendritic Cells May Be Implicated in Human Systemic Sclerosis Development. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2123-2132.	0.3	17
67	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	2.0	17
68	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. <i>Journal of Rheumatology</i> , 2021, 48, 741-750.	1.0	17
69	Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases. <i>Clinical Rheumatology</i> , 2021, 40, 3547-3564.	1.0	17
70	La Reumatología en la Comunidad de Madrid: disponibilidad actual de reumatólogos y necesidades futuras aplicando un modelo predictivo. <i>Reumatología Clínica</i> , 2013, 9, 353-358.	0.2	16
71	Bone Mineral Density Distribution Curves in Spanish Adults With Down Syndrome. <i>Journal of Clinical Densitometry</i> , 2018, 21, 493-500.	0.5	16
72	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 23-36.	1.3	16

#	ARTICLE	IF	CITATIONS
73	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3704.	1.0	16
74	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 274-283.	0.4	16
75	Reproducibility of Metacarpophalangeal Bone Mass Measurements Obtained by Dual-Energy X-Ray Absorptiometry in Healthy Volunteers and Patients With Early Arthritis. <i>Journal of Clinical Densitometry</i> , 2007, 10, 298-305.	0.5	15
76	Osteoarthritis: More than Cartilage Degeneration. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2017, 15, 69-81.	1.3	15
77	Bone Mass Assessment in a Cohort of Adults With Down Syndrome: A Cross-Sectional Study. <i>Intellectual and Developmental Disabilities</i> , 2017, 55, 315-324.	0.6	15
78	Treatment of giant cell arteritis. <i>Biochemical Pharmacology</i> , 2019, 165, 230-239.	2.0	15
79	Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMATology (CARMA) prospective studyâ€”results at 5 years of follow-up. <i>Rheumatology</i> , 2021, 60, 2906-2915.	0.9	15
80	Biologic Therapy in COVID-19. <i>Archivos De Bronconeumologia</i> , 2021, 57, 1-2.	0.4	15
81	Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 10525.	1.6	14
82	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	0.9	14
83	Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 395-403.	1.6	14
84	Update on the use of abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 599-621.	1.3	13
85	New Criteria Needed for Antisynthetase Syndrome. <i>JAMA Neurology</i> , 2018, 75, 258.	4.5	13
86	Sex and Cardiovascular Involvement in Inflammatory Joint Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 278-292.	2.9	13
87	Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis. <i>Scientific Reports</i> , 2020, 10, 9636.	1.6	13
88	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	1.6	13
89	Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 40303.	1.6	12
90	<i>HLA-B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Antiâ€“Carbamylated Protein Antibodyâ€“Positive/Antiâ€“Cyclic Citrullinated Peptideâ€“Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 963-969.	2.9	12

#	ARTICLE	IF	CITATIONS
91	Influence of MUC5B gene on antisyndetase syndrome. Scientific Reports, 2020, 10, 1415.	1.6	12
92	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis). Arthritis Research and Therapy, 2015, 17, 286.	1.6	11
93	Vitamin D receptor GATC haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. Atherosclerosis, 2016, 245, 139-142.	0.4	11
94	Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. Journal of Clinical Medicine, 2021, 10, 382.	1.0	11
95	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0161727.	1.1	11
96	Advances in the Treatment of Giant Cell Arteritis. Journal of Clinical Medicine, 2022, 11, 1588.	1.0	11
97	Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis. Scientific Reports, 2020, 10, 17799.	1.6	10
98	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatology, 2020, 4, 42.	0.6	10
99	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatology and Therapy, 2021, 8, 1661-1675.	1.1	10
100	Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases. Reumatología Clínica, 2017, 13, 210-213.	0.2	9
101	Vasculitis flare after COVID-19: report of two cases in patients with preexistent controlled IgA vasculitis and review of the literature. Rheumatology International, 2022, 42, 1643-1652.	1.5	9
102	Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Frontiers in Immunology, 0, 13, .	2.2	9
103	Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain. Journal of Clinical Rheumatology, 2019, 25, 258-263.	0.5	8
104	Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina Clínica, 2019, 152, 353-360.	0.3	8
105	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	0.8	8
106	Lack of association between IL6 gene and Henoch-Schönlein purpura. Clinical and Experimental Rheumatology, 2014, 32, S141-2.	0.4	8
107	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clinical and Experimental Rheumatology, 2021, 39, 612-620.	0.4	8
108	Gene polymorphisms and therapy in rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 225-229.	1.5	7

#	ARTICLE	IF	CITATIONS
109	Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial. <i>Reumatología Clínica</i> , 2018, 14, 346-359.	0.2	7
110	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 897-901.	1.6	7
111	A Review of the Dermatological Complications of Giant Cell Arteritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 303-312.	0.8	7
112	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. <i>Arthritis Research and Therapy</i> , 2021, 23, 111.	1.6	7
113	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. <i>Rheumatology</i> , 2022, 61, 1204-1210.	0.9	7
114	Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study. <i>European Journal of Internal Medicine</i> , 2021, 91, 63-69.	1.0	7
115	Managing of giant cell arteritis and polymyalgia rheumatica. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1133-1144.	0.5	6
116	Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 975-976.	2.9	6
117	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	0.9	6
118	The role of biologics in the treatment of giant cell arteritis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 65-72.	1.4	6
119	Utilidad de la ecografía extraarticular aplicada a las enfermedades inflamatorias sistémicas en la práctica clínica. <i>Reumatología Clínica</i> , 2021, 17, 229-236.	0.2	6
120	Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 731-739.	0.4	6
121	Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152037.	1.6	6
122	Clinical evolution of antisynthetase syndrome after SARS-CoV2 infection: a 6-month follow-up analysis. <i>Clinical Rheumatology</i> , 2022, 41, 2601-2604.	1.0	6
123	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 188-210.	0.2	5
124	Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110337.	1.2	5
125	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 225-232.	1.3	5
126	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	1.3	5



#	ARTICLE	IF	CITATIONS
127	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. <i>Scientific Reports</i> , 2021, 11, 11510.	1.6	5
128	Henoch-Schönlein purpura (IgA vasculitis): the paradox of the different incidence and clinical spectrum in children and adults. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 3-4.	0.4	5
129	Giant cell arteritis: more than a cranial disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 15-17.	0.4	5
130	Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1201-1205.	0.4	5
131	Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis" by Bugatti et al.. <i>Arthritis Research and Therapy</i> , 2017, 19, 152.	1.6	4
132	Interacciones farmacológicas de los anticuerpos monoclonales. <i>Medicina Clínica</i> , 2018, 151, 148-155.	0.3	4
133	Rituximab in Takayasu arteritis: an unmet hope. <i>Rheumatology</i> , 2018, 57, 1133-1134.	0.9	4
134	Volumetric BMD by 3D-DXA and Trabecular Bone Score in Adults With Down Syndrome. <i>Journal of Clinical Densitometry</i> , 2021, 24, 630-637.	0.5	4
135	Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 615-622.	0.4	4
136	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 615-620.	0.4	4
137	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.4	4
138	Utility of tocilizumab in autoimmune eye diseases. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 789-799.	1.4	4
139	Subchondral bone remodelling and osteoarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	1.6	3
140	Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , 2016, 43, 990-991.	1.0	3
141	Fármacos biosimilares: un nuevo escenario en las terapias biológicas. <i>Reumatología Clínica</i> , 2017, 13, 287-293.	0.2	3
142	Biosimilars: A New Scenario in Biologic Therapies. <i>Reumatología Clínica (English Edition)</i> , 2017, 13, 287-293.	0.2	3
143	Adherencia al tratamiento con fármacos moduladores de la enfermedad sintomáticos en la artritis reumatoide. Resultados del estudio OBSERVAR. <i>Reumatología Clínica</i> , 2019, 15, 264-270.	0.2	3
144	Reproducibility of Metacarpal Bone Mineral Density Measurements Obtained by Dual-Energy X-Ray Absorptiometry in Healthy Volunteers and Patients With Early Arthritis. <i>Journal of Clinical Densitometry</i> , 2020, 23, 678-684.	0.5	3

#	ARTICLE	IF	CITATIONS
145	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608.	1.0	3
146	Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 587-596.	0.2	3
147	Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 899-901.	0.5	3
148	Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment. <i>Genes</i> , 2022, 13, 146.	1.0	3
149	Tocilizumab in giant cell arteritis: differences between the GACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.4	3
150	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 21-26.	0.4	3
151	Treatment of migraine with monoclonal antibodies. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 707-716.	1.4	3
152	Differences in the management of early and established rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 172-178.	0.2	2
153	Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases: comment on "Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative" by Baillet et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e55-e55.	0.5	2
154	Why is Rheumatoid Arthritis Mortality Still High Despite the Advent of New Therapies? Comment on the Article by Widdifield et al. <i>Arthritis Care and Research</i> , 2016, 68, 726-727.	1.5	2
155	Facing arthritis: helping patients to handle their disease and concerns. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 903-905.	1.3	2
156	Desarrollo y viabilidad de cuatro checklists para la evaluación de la comorbilidad en pacientes con artritis reumatoide, espondiloartritis axial y artritis psoriásica: Proyecto GECHOAI. <i>Reumatología Clínica</i> , 2022, 18, 114-123.	0.2	2
157	Síndrome de Cogan: análisis descriptivo y experiencia clínica de 7 casos diagnosticados y tratados en 2 hospitales de tercer nivel. <i>Reumatología Clínica</i> , 2021, 17, 318-321.	0.2	2
158	Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 774-782.	0.4	2
159	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 69-75.	0.4	2
160	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 581-588.	0.4	2
161	Estrogènes, arthrose et inflammation. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 350-356.	0.0	1
162	Adult-onset Still's disease. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 217-222.	0.1	1

#	ARTICLE	IF	CITATIONS
163	Pharmacological interactions of monoclonal antibodies. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 148-155.	0.1	1
164	Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECOAI Project. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 114-123.	0.2	1
165	Prevalence of Metabolic Syndrome in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e388-e396.	0.5	1
166	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. <i>Scientific Reports</i> , 2021, 11, 16163.	1.6	1
167	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 311-333.	1.0	1
168	Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 662-669.	0.4	1
169	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
170	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
171	¿Es la reumatología una especialidad sostenible?. <i>Reumatología Clínica</i> , 2014, 10, 66-67.	0.2	0
172	Cardiovascular risk assessment in rheumatoid arthritis: What goals should be achieved?. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e20-e21.	1.6	0
173	Vitamin D and Autoimmune Rheumatic Diseases. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 356-357.	0.2	0
174	Vitamina D y enfermedades reumáticas. <i>Reumatología Clínica</i> , 2016, 12, 356-357.	0.2	0
175	Respuesta. <i>Medicina Clínica</i> , 2017, 148, e15-e16.	0.3	0
176	Innovations in the therapeutic outlook of rheumatoid arthritis. <i>Reumatología Clínica (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	0.2	0
177	Novedades en el panorama terapéutico de la artritis reumatoide. <i>Reumatología Clínica</i> , 2017, 13, 63-65.	0.2	0
178	Tratamiento biológico en la enfermedad pulmonar intersticial difusa asociada a las enfermedades del tejido conectivo. <i>Archivos De Bronconeumología</i> , 2018, 54, 549-550.	0.4	0
179	SAT0271...RELATIONSHIP BETWEEN ANTI-MDA5 ANTIBODIES AND CANCER: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL AND MULTIDISCIPLINARY COHORT. , 2019, , .		0
180	FRI0006...PROTECTIVE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) RS2495477 POLYMORPHISM IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SUBCLINICAL ATHEROSCLEROSIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
181	AB1201â€¦MANAGEMENT OF COMORBIDITY IN INFLAMMATORY ARTHRITIS: GECOAI PROJECT. , 2019, , .		0
182	Effect of cardiovascular disease on chronic inflammatory joint disease: reverse causality?. Expert Review of Clinical Immunology, 2020, 16, 855-858.	1.3	0
183	Dermatomiositis asociada a anticuerpos anti-MDA5, una entidad cl�nica heterog�nea. Medicina Cl�nica, 2021, 158, 186-186.	0.3	0
184	Respuesta a Â«Intersticiopat�a pulmonar subcl�nica en pacientes con esclerosis sist�mica. Estudio piloto sobre el papel del ultrasonidoÂ». Reumatolog�a Cl�nica, 2021, , .	0.2	0
185	Monitoring and safety of CAR-T therapy in clinical practice. Expert Opinion on Drug Safety, 2022, 21, 363-371.	1.0	0
186	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. Arthritis Research and Therapy, 2021, 23, 268.	1.6	0
187	Response to â€œSubclinical interstitial lung disease in patients with systemic sclerosis. A pilot study on the role of ultrasoundâ€. Reumatolog�a Cl�nica (English Edition), 2021, , .	0.2	0
188	Dermatomyositis associated with anti-MDA5 antibodies: A heterogenous clinical picture. Medicina Cl�nica (English Edition), 2022, 158, 186-186.	0.1	0
189	Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 166-170.	0.4	0
190	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 182-187.	0.4	0
191	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clinical and Experimental Rheumatology, 2021, 39, 612-620.	0.4	0
192	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
193	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
194	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	0
195	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
196	Position of the Spanish Society of Rheumatology (SER) and the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) on romosozumab. Reumatolog�a Cl�nica (English Edition), 2022, , .	0.2	0